Compu-Mail is pleased to announce the Leukemia & Lymphoma Society as a Charity Connection 2013 recipient. This deserving organization will receive a $500 donation.
Luann Burgio, Deputy Executive Director of The Leukemia & Lymphoma Society’s Western & Central New York Chapter, stated, “Through the generous support of companies like Compu-Mail, we are able to continue to support our local patients and come closer to our goal of a world without blood cancers. We are very thankful for this wonderful donation.”
The organization was nominated through our website by Christopher Skipper of CASCO Security who shared his personal story:
Two years ago my fiancée was 8 months pregnant with our son, Anthony Christopher. She was on a weekly check up with her doctor. On Feb 23rd at 11am, 2011, we had a check up. When we went in to the doctor’s office, my fiancée was not feeling that well so they decided to do a check on her to only find out that our son’s heart was no longer beating. They did blood work to find out that she had a rare case of AML, Acute Myeloid Leukemia. Our son did not make it and my fiancée almost didn’t either. With the help of the Society and Roswell Park, my fiancée found two perfect matches for a bone marrow transplant. Her transplant was on June 8th of that same year and for the past two years with help from the Leukemia & Lymphoma Society and great doctors, and prayer to our GOD above, she is in remission from that terrible disease. I feel that they deserve all the financial help they can get from people and companies. Please find it in your heart to give to this great society.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (LLS), based in White Plains, NY, is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Since it was founded in 1949, LLS has invested more than $750 million in research specifically targeting blood cancers.